Zoetis Inc
NYSE:ZTS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
145.54
199.94
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zoetis Inc
Zoetis Inc
Revenue
Zoetis Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Zoetis Inc
Revenue Breakdown
Breakdown by Geography
Zoetis Inc
|
Total Revenue:
8.5B
USD
|
|
Total Geographical Area:
8.5B
USD
|
|
United States:
4.6B
USD
|
|
Other Emerging Markets:
784m
USD
|
|
Other Developed Markets:
512m
USD
|
|
Brazil:
393m
USD
|
|
Australia:
323m
USD
|
|
China:
320m
USD
|
|
United Kingdom:
277m
USD
|
|
Canada:
255m
USD
|
|
Germany:
202m
USD
|
|
Mexico:
162m
USD
|
|
Japan:
158m
USD
|
|
France:
142m
USD
|
|
Chile:
140m
USD
|
|
Spain:
122m
USD
|
|
Italy:
121m
USD
|
Breakdown by Segments
Zoetis Inc
|
Total Revenue:
8.5B
USD
|
|
Total Products And Services:
8.5B
USD
|
|
Companion Animal:
5.6B
USD
|
|
Horses:
5.3B
USD
|
|
Livestock:
2.9B
USD
|
|
Parasiticides:
1.9B
USD
|
|
Vaccines:
1.8B
USD
|
|
Cattle:
1.5B
USD
|
|
Dermatology:
1.4B
USD
|
|
Other Pharmaceuticals:
1.3B
USD
|
|
Anti-Infectives:
1.1B
USD
|
|
Swine:
543m
USD
|
|
Poultry:
524m
USD
|
|
Animal Health Diagnostics:
376m
USD
|
|
Medicated Feed Additives:
354m
USD
|
|
Dogs And Cats:
285m
USD
|
|
Other Non-Pharmaceuticals:
254m
USD
|
|
Fish:
220m
USD
|
|
Other:
100m
USD
|
|
Contract Manufacturing And Human Health Diagn...:
78m
USD
|
Zoetis Inc
Glance View
In the vast panorama of the global animal health industry, Zoetis Inc. emerges as a formidable player, intricately weaving a narrative of innovation and growth. Originally part of Pfizer, Zoetis embarked on its solo journey in 2013, driven by a singular mission to understand, anticipate, and amplify the needs of both livestock and companion animals. At the heart of its operations lies an impressive pipeline of products—from vaccines and diagnostics to genetic tests and precision livestock farming software—designed to improve the health of animals. Its comprehensive approach ensures not only the well-being of the animals but also supports the burgeoning needs of veterinary practitioners and livestock producers worldwide. Financially, Zoetis masters the art of monetizing its deep-rooted expertise in animal biology and science. Revenue streams flow predominantly from the sale of these innovative products, with livestock and companion animal segments each contributing significant streams of income. The company capitalizes on its extensive global footprint, reaching customers in over 100 countries, ensuring diversified and steady cash flows. Its continued investment in R&D underscores a long-term commitment to innovation, enhancing its product offerings and driving future growth. In a world increasingly conscious of the importance of animal welfare and food security, Zoetis stands at a strategic intersection, aligning its business model with the evolving dynamics of both consumer preferences and regulatory landscapes.
See Also
What is Zoetis Inc's Revenue?
Revenue
9.2B
USD
Based on the financial report for Sep 30, 2024, Zoetis Inc's Revenue amounts to 9.2B USD.
What is Zoetis Inc's Revenue growth rate?
Revenue CAGR 10Y
7%
Over the last year, the Revenue growth was 9%. The average annual Revenue growth rates for Zoetis Inc have been 6% over the past three years , 8% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
